Viridian Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$16.41(as of Aug 8, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Viridian Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$16.41
Ticker SymbolVRDN
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees143
CountyUSA
Market Cap$1,340.1M

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Viridian Therapeutics Inc In Our Stock Scanner

As of Aug 11, 2025
As of ---
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.